This brand name is authorized in Brazil, Ecuador, South Africa
The drug DERIVA contains one active pharmaceutical ingredient (API):
|
1
Adapalene
UNII 1L4806J2QF - ADAPALENE
|
|
Adapalene is a retinoid-like compound which in, in vivo and in vitro models of inflammation, has been demonstrated to possess anti-inflammatory properties. Mechanically, adapalene binds like tretinoin to specific retinoic acid nuclear receptors but, unlike tretinoin not to cytosolic receptor binding proteins. Adapalene is used in the treatment of acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D10AD03 | Adapalene | D Dermatologicals → D10 Anti-acne preparations → D10A Anti-acne preparations for topical use → D10AD Retinoids for topical use in acne |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 521905501173316 |
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 28988-08-09 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 44/13.11/0766 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
